EP4512471A3 - Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen - Google Patents

Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen Download PDF

Info

Publication number: EP4512471A3
Authority: EP; European Patent Office
Prior art keywords: dermatitis; areas; treatment; skin afflictions; afflictions
Prior art date: 2014-06-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP24207715.4A

Other languages

English (en)

French (fr)

Other versions

EP4512471A2 (de

Inventor

Frank Anthony SPALLITTA

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Attillaps Holdings

Original Assignee

Attillaps Holdings

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-19

Filing date

2015-06-18

Publication date

2025-05-07

2015-06-18 Application filed by Attillaps Holdings filed Critical Attillaps Holdings

2025-02-26 Publication of EP4512471A2 publication Critical patent/EP4512471A2/de

2025-05-07 Publication of EP4512471A3 publication Critical patent/EP4512471A3/de

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Botany (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Mycology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Inorganic Chemistry (AREA)
Otolaryngology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP24207715.4A 2014-06-19 2015-06-18 Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen Pending EP4512471A3 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201462014520P	2014-06-19	2014-06-19
EP15809417.7A EP3157534B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen
EP22182867.6A EP4088724B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen
PCT/US2015/036448 WO2015195928A1 (en)	2014-06-19	2015-06-18	Acetylcholinesterase inhibitors for treatment of dermatological conditions

Related Parent Applications (2)

Application Number	Title	Priority Date	Filing Date
EP15809417.7A Division EP3157534B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen
EP22182867.6A Division EP4088724B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen

Publications (2)

Publication Number	Publication Date
EP4512471A2 EP4512471A2 (de)	2025-02-26
EP4512471A3 true EP4512471A3 (de)	2025-05-07

Family

ID=54936099

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP22182867.6A Active EP4088724B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen
EP24207715.4A Pending EP4512471A3 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur behandlung von dermatologischen erkrankungen
EP15809417.7A Active EP3157534B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP22182867.6A Active EP4088724B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur oralen behandlung von dermatologischen zuständen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP15809417.7A Active EP3157534B1 (de)	2014-06-19	2015-06-18	Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen

Country Status (17)

Country	Link
US (3)	US10500183B2 (de)
EP (3)	EP4088724B1 (de)
AU (1)	AU2015277038B2 (de)
CA (1)	CA2952838C (de)
CY (1)	CY1126038T1 (de)
DK (1)	DK3157534T3 (de)
ES (1)	ES2925021T3 (de)
HR (1)	HRP20220854T1 (de)
HU (1)	HUE059303T2 (de)
LT (1)	LT3157534T (de)
PL (1)	PL3157534T3 (de)
PT (1)	PT3157534T (de)
RS (1)	RS63433B1 (de)
SI (1)	SI3157534T1 (de)
SM (1)	SMT202200283T1 (de)
WO (1)	WO2015195928A1 (de)
ZA (1)	ZA201700183B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019126541A1 (en) *	2017-12-20	2019-06-27	Attillaps Holdings	Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
US11446241B2 (en)	2013-07-29	2022-09-20	Attillaps Holdings Inc.	Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
CA2917815C (en) *	2013-07-29	2022-08-30	Attillaps Holdings	Organophosphates for treating afflictions of the skin
PT3157534T (pt)	2014-06-19	2022-08-04	Attillaps Holdings	Inibidores de acetilcolinestérase para o tratamento de condições da dermatológicas
US20170232024A1 (en)	2014-08-04	2017-08-17	Jerry Tan Eye Surgery Pte Ltd	Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
JP2019515052A (ja) *	2016-05-13	2019-06-06	デルノバ・インコーポレイテッドＤｅｌＮｏｖａ，Ｉｎｃ．	化学的除神経から生じる副作用の処置
CN109200051A (zh) *	2017-07-03	2019-01-15	南京和博生物医药有限公司	石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
BE1025705B1 (fr)	2017-09-12	2019-06-18	Cosucra Groupe Warcoing Sa	Amélioration de la maladie et des conditions générales de la volaille et du bétail à l'aide d'une racine chicorée séchée
CN119157876A (zh)	2017-12-15	2024-12-20	塔苏斯制药有限公司	用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
WO2019136225A1 (en) *	2018-01-05	2019-07-11	Attillaps Holdings	Treating dermatological conditions with chloroquine and/or hydroxychloroquine
US20210069176A1 (en) *	2018-01-05	2021-03-11	Attillaps Holdings	Treating Autoimmune Disorders with Chloroquine and/or Hydroxychloroquine
US12502377B2 (en)	2019-04-04	2025-12-23	Tarsus Pharmaceuticals, Inc.	Method of eradicating ticks that attach to humans using lotilaner formulations
WO2021102072A1 (en) *	2019-11-19	2021-05-27	Rythera Therapeutics, Inc.	Composition and method for skin treatment
EP4022088B1 (de) *	2019-12-19	2025-09-17	Hill's Pet Nutrition, Inc.	Tomatentrester enthaltende zusammensetzungen zur verwendung in verfahren zur behandlung und verminderung des risikos von erkrankungen im zusammenhang mit erhöhtem 4-ethylphenylsulfat bei hunden und verfahren zur identifizierung von hunden mit einem risiko für solche erkrankungen
WO2021189077A1 (en) *	2020-03-18	2021-09-23	Chemistryrx	Methods for treating acne
CN114099490A (zh) *	2021-12-30	2022-03-01	温州医科大学附属第二医院（温州医科大学附属育英儿童医院）	卡巴拉汀在制备促进缺血超长随意皮瓣存活的药物的作用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070287733A1 (en) *	2004-10-12	2007-12-13	Ernir Snorrason	Method of Treating Skin Diseases
US20130344128A1 (en) *	2005-04-30	2013-12-26	Tissuetech, Inc.	Method for treating ocular demodex
WO2015017328A2 (en) *	2013-07-29	2015-02-05	Spallitta Frank Anthony	Organophosphates for treating afflictions of the skin

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6406713B1 (en)	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
DE4217396A1 (de)	1992-05-26	1993-12-02	Bayer Ag	Metrifonat enthaltendes Arzneimittel
WO1999039738A1 (en)	1998-02-09	1999-08-12	Bracco Research S.A.	Targeted delivery of biologically active media
US5952372A (en)	1998-09-17	1999-09-14	Mcdaniel; William Robert	Method for treating rosacea using oral or topical ivermectin
US6133310A (en)	1999-08-26	2000-10-17	Parks; L. Dean	Method of treatment of rosacea
EP1389911A1 (de)	2001-05-09	2004-02-25	Medicis Pharmaceutical Corporation	Ectoparasitizide zusammensetzungen und verfahren zu ihrer verwendung
AU2003215011A1 (en) *	2002-02-08	2003-09-02	Mcneil-Ppc, Inc.	Topical ivermectin composition
BR0311899A (pt)	2002-06-19	2005-04-12	Fideline	Composição, métodos de repulsa de aracnìdeos, de tratamento ou de prevenção ácaros de galinha ou de ácaros de aves do norte em galinhas, frangos e pintos jovens e de atração de aracnìdeos, e, solução.
US8119150B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Non-flammable insecticide composition and uses thereof
US8486374B2 (en)	2003-08-04	2013-07-16	Foamix Ltd.	Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US7899527B2 (en) *	2004-05-13	2011-03-01	Palo Alto Investors	Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
US8012498B2 (en) *	2004-07-12	2011-09-06	Sandhya Goyal	Topical gel formulation comprising organophosphate insecticide and preparation thereof
GB2419093A (en)	2004-10-12	2006-04-19	Ernir Snorrason	Acetylcholinesterase inhibitors for the treatment of skin
FR2886851B1 (fr)	2005-06-10	2007-10-05	Galderma Sa	Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
ES2823760T3 (es)	2006-09-01	2021-05-10	Fmc Corp	Formulaciones para administración tópica local que contienen indoxacarb
US20080292560A1 (en)	2007-01-12	2008-11-27	Dov Tamarkin	Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
BRPI0806666A8 (pt)	2007-01-16	2018-02-06	Tyratech Inc	Composições e método para controle de praga
US20130052271A1 (en) *	2011-08-29	2013-02-28	Richard S. Sternasty	Compositions and Methods for Treating Pain
FR2915489B1 (fr)	2007-04-27	2009-07-31	Univ Henri Poincare Nancy I Et	Phosphotriesterases hyperthermophiles mutees et leurs utilisations
EP2337544A2 (de) *	2007-04-30	2011-06-29	Living Proof, Inc.	Verwendung von matrix-metalloproteinase-hemmern in der hautpflege
US7919522B2 (en)	2007-05-03	2011-04-05	Merial Limited	Compositions comprising C-13 alkoxyether macrolide compounds and phenylpyrazole compounds
JP2010527928A (ja)	2007-05-18	2010-08-19	ヴィヴァス・インコーポレイテッド	ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
GB0713790D0 (en)	2007-07-16	2007-08-22	Nettforsk As	Method
TWI556741B (zh)	2007-08-17	2016-11-11	英特威特國際股份有限公司	異唑啉組成物及其作為抗寄生蟲藥上的應用
US8128968B2 (en) *	2007-08-29	2012-03-06	Tissuetech, Inc.	Compositions and methods for treating Demodex infestations
TW200924647A (en)	2007-08-30	2009-06-16	Schering Plough Ltd	Local topical administration formulations containing fipronil
DE102007043006B4 (de)	2007-09-06	2010-04-08	Freie Universität Berlin	Vorrichtung und Verfahren zur Exponierung eines Insekts mit einem Wirkstoff sowie Verfahren zur Bestimmung der Wirkung eines Wirkstoffs auf ein Insekt
EP2072501A1 (de)	2007-12-21	2009-06-24	Bayer CropScience AG	Aminobenzamidderivate als nützliche Wirkstoffe zur Parasitenkontrolle bei Tieren
CN102083408A (zh)	2008-04-15	2011-06-01	创新公司	包含源自微生物席的胞外多糖的化妆品组合物及其应用
US8247405B2 (en)	2008-12-10	2012-08-21	Conopco, Inc.	Skin lightening compositions with acetylcholinesterase inhibitors
CA2806258A1 (en)	2010-07-23	2012-01-26	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound and application thereof
GB201015079D0 (en)	2010-09-10	2010-10-27	Helperby Therapeutics Ltd	Novel use
JP2014028758A (ja)	2010-11-19	2014-02-13	Nissan Chem Ind Ltd	寄生虫及び衛生害虫防除剤
WO2012135763A1 (en)	2011-03-31	2012-10-04	Agraquest, Inc.	Pesticidal mixtures
FR2975004B1 (fr) *	2011-05-13	2013-06-28	Expanscience Lab	Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant
AR088669A1 (es)	2011-11-21	2014-06-25	Lilly Co Eli	Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es)	2011-11-21	2014-06-25	Lilly Co Eli	Moleculas pequeñas que contienen boro
JO3626B1 (ar)	2012-02-23	2020-08-27	Merial Inc	تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
US9271953B2 (en) *	2013-03-13	2016-03-01	Genetic Disease Investigators, LLC	Methods for correction of organ dysfunction
US11446241B2 (en) *	2013-07-29	2022-09-20	Attillaps Holdings Inc.	Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
PT3157534T (pt) *	2014-06-19	2022-08-04	Attillaps Holdings	Inibidores de acetilcolinestérase para o tratamento de condições da dermatológicas

2015
- 2015-06-18 PT PT158094177T patent/PT3157534T/pt unknown
- 2015-06-18 LT LTEPPCT/US2015/036448T patent/LT3157534T/lt unknown
- 2015-06-18 RS RS20220713A patent/RS63433B1/sr unknown
- 2015-06-18 EP EP22182867.6A patent/EP4088724B1/de active Active
- 2015-06-18 PL PL15809417.7T patent/PL3157534T3/pl unknown
- 2015-06-18 HR HRP20220854TT patent/HRP20220854T1/hr unknown
- 2015-06-18 SM SM20220283T patent/SMT202200283T1/it unknown
- 2015-06-18 EP EP24207715.4A patent/EP4512471A3/de active Pending
- 2015-06-18 US US15/319,897 patent/US10500183B2/en active Active
- 2015-06-18 EP EP15809417.7A patent/EP3157534B1/de active Active
- 2015-06-18 CA CA2952838A patent/CA2952838C/en active Active
- 2015-06-18 AU AU2015277038A patent/AU2015277038B2/en active Active
- 2015-06-18 DK DK15809417.7T patent/DK3157534T3/da active
- 2015-06-18 WO PCT/US2015/036448 patent/WO2015195928A1/en not_active Ceased
- 2015-06-18 SI SI201531857T patent/SI3157534T1/sl unknown
- 2015-06-18 ES ES15809417T patent/ES2925021T3/es active Active
- 2015-06-18 HU HUE15809417A patent/HUE059303T2/hu unknown
2017
- 2017-01-09 ZA ZA2017/00183A patent/ZA201700183B/en unknown
2019
- 2019-10-14 US US16/601,405 patent/US11045442B2/en active Active
2021
- 2021-06-08 US US17/342,350 patent/US20220096420A1/en active Pending
2022
- 2022-08-10 CY CY20221100545T patent/CY1126038T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070287733A1 (en) *	2004-10-12	2007-12-13	Ernir Snorrason	Method of Treating Skin Diseases
US20130344128A1 (en) *	2005-04-30	2013-12-26	Tissuetech, Inc.	Method for treating ocular demodex
WO2015017328A2 (en) *	2013-07-29	2015-02-05	Spallitta Frank Anthony	Organophosphates for treating afflictions of the skin

Also Published As

Publication number	Publication date
EP3157534A1 (de)	2017-04-26
AU2015277038B2 (en)	2020-09-17
EP4088724A1 (de)	2022-11-16
US10500183B2 (en)	2019-12-10
PT3157534T (pt)	2022-08-04
DK3157534T3 (da)	2022-08-22
CY1126038T1 (el)	2023-11-15
EP4512471A2 (de)	2025-02-26
US20200281885A1 (en)	2020-09-10
LT3157534T (lt)	2022-09-12
ZA201700183B (en)	2020-05-27
SI3157534T1 (sl)	2022-08-31
CA2952838A1 (en)	2015-12-23
CA2952838C (en)	2023-09-05
US20170135978A1 (en)	2017-05-18
ES2925021T3 (es)	2022-10-13
HRP20220854T1 (hr)	2022-10-14
US11045442B2 (en)	2021-06-29
AU2015277038A1 (en)	2017-02-02
EP4088724B1 (de)	2024-10-23
EP4088724C0 (de)	2024-10-23
WO2015195928A1 (en)	2015-12-23
HUE059303T2 (hu)	2022-11-28
EP3157534A4 (de)	2018-03-14
RS63433B1 (sr)	2022-08-31
EP3157534B1 (de)	2022-07-06
PL3157534T3 (pl)	2022-09-12
SMT202200283T1 (it)	2022-09-14
US20220096420A1 (en)	2022-03-31

Legal Events

Date	Code	Title	Description
2025-01-24	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2025-01-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2025-02-26	AC	Divisional application: reference to earlier application	Ref document number: 3157534 Country of ref document: EP Kind code of ref document: P Ref document number: 4088724 Country of ref document: EP Kind code of ref document: P
2025-02-26	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2025-03-31	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0017000000 Ipc: A61K0031270000
2025-04-04	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2025-05-07	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2025-05-07	RIC1	Information provided on ipc code assigned before grant	Ipc: A01N 57/20 20060101ALI20250331BHEP Ipc: A61P 33/00 20060101ALI20250331BHEP Ipc: A61P 17/00 20060101ALI20250331BHEP Ipc: A61K 31/683 20060101ALI20250331BHEP Ipc: A61K 31/662 20060101ALI20250331BHEP Ipc: A61K 31/55 20060101ALI20250331BHEP Ipc: A61K 31/473 20060101ALI20250331BHEP Ipc: A61K 31/27 20060101AFI20250331BHEP
2025-11-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2025-12-17	17P	Request for examination filed	Effective date: 20251106
2026-03-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2026-04-15	17Q	First examination report despatched	Effective date: 20260311

Publication	Publication Date	Title
WO2015017328A3 (en)	2015-11-05	Organophosphates for treating afflictions of the skin
CY1126038T1 (el)	2023-11-15	Αναστολεις ακετυλοχολινεστερασης για τη θεραπεια δερματολογικων καταστασεων
WO2016010984A3 (en)	2016-03-10	Compositions and methods for treating rosacea
BR112018072560A2 (pt)	2019-02-19	terapia de combinação para tratamento do câncer
CY1121135T1 (el)	2019-12-11	Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BR112016028964A2 (pt)	2017-10-17	métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação
BR112015000808A2 (pt)	2017-06-27	regime de dosagem para inibidores de janus quinase (jak)
WO2014107740A3 (en)	2015-02-26	Methods for reducing cellular proliferation and treating certain diseases
MX375706B (es)	2025-03-06	Compuestos de inhibidor de autotaxina.
AU2016255707A8 (en)	2019-08-08	Uses of cannabidiol for treatment of infantile spasms
MX2019007391A (es)	2019-08-16	Sistema terapeutico transdermico que contiene asenapina.
MX2018002067A (es)	2018-09-05	Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
EA201691808A8 (ru)	2017-04-28	Кортикостероидные композиции для местного применения
EA201991790A1 (ru)	2020-04-03	Терапевтические препараты апремиласта для местного применения
MX2017017138A (es)	2018-04-30	Conjugados homogeneos especificos de sitio con inhibidores de ksp.
CL2015002346A1 (es)	2015-12-28	Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
MX376183B (es)	2025-03-07	Composiciones para el tratamiento de rosacea.
AU2016206832A8 (en)	2017-08-03	Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
AU2018271862A1 (en)	2019-12-12	Combination therapy
EP4086250A3 (de)	2023-03-22	Multifunktionale inhibitoren von biologischen mek/pi3k und mtor/mek/pi3k pfaden und therapeutische verfahren unter verwendung derselben
MX377447B (es)	2025-03-10	Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis.
BR112017018758A2 (pt)	2018-04-17	alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide
AU2018244925A1 (en)	2019-11-21	Compositions for the treatment of drug-resistant tumors and methods of use thereof
BR112019025478A8 (pt)	2022-12-06	Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer
MX2022000394A (es)	2022-02-10	Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.